MABSol® Biotinylated Human CD19, Fc Tag (CD9-H8259) is expressed from human HEK293 cells. It contains AA Pro 20 - Lys 291 (Accession # AAH06338). It is the biotinylated form of Human CD19 Protein, Fc Tag (Cat # CD9-H5259).
Predicted N-terminus: Pro 20
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 56.3 kDa. The protein migrates as 56-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
The biotin to protein ratio is 2.5-3.5 as determined by the HABA assay.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by reduced SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human CD19, Fc tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized FMC63 mAb at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD19, Fc tag (Cat# CD9-H8259) with a linear range of 0.15-2.5 μg/mL.
Authors: MacLeod DT et al.
Journal: Mol Ther 2017
Application: Flow Cytometry
B-lymphocyte antigen CD19, is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
- (1) Pesando JM, et al., J. Exp. Med. 170 (6): 2159–64.
- (2) van Zelm MC, et al., 2006, N. Engl. J. Med. 354 (18): 1901–12.
- (3) Bradbury LE, et al., 1992, J. Immunol. 149 (9): 2841–50.
- (4) Horváth G, et al., 1998, J. Biol. Chem. 273 (46): 30537–43.
- (5) Imai T, et al., 1995, J. Immunol. 155 (3): 1229–39.
- (6) Doody GM, et al., 2000, EMBO J. 19 (22): 6173–84.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.